6,452
Views
7
CrossRef citations to date
0
Altmetric
Research Articles

Insertion experience of women and health care professionals in the Kyleena® Satisfaction Study

, , , , ORCID Icon, , , & show all
Pages 182-189 | Received 16 Dec 2019, Accepted 25 Feb 2020, Published online: 30 Mar 2020

References

  • Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.
  • Buhling KJ, Klovekorn L, Daniels B, et al. Contraceptive counselling and self-prescription of contraceptives of German gynaecologists: results of a nationwide survey. Eur J Contracept Reprod Health Care. 2014;19(6):448–456.
  • National Institute for Health and Care Excellence. Long-acting reversible contraception. Clinical Guideline CG30 [Internet]. 2014 [cited 2018 Nov 8]. Available from: https://www.nice.org.uk/guidance/cg30/resources/longacting-reversible-contraception-pdf-975379839685.
  • Faculty of Sexual and Reproductive Healthcare. Intrauterine Contraception [Internet]. 2015. [cited 2018 Nov 8]. Available from: http://www.fsrh.org/pdfs/CEUGuidanceIntrauterineContraceptionpdf.
  • World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition. Geneva: WHO [Internet]. 2015. [cited 2018 Dec 10]. Available from: https://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/.
  • Black A, Guilbert E, Costescu D, et al. Canadian contraception consensus (part 3 of 4): Chapter 7 – intrauterine contraception. J Obstet Gynaecol Can. 2016;38(2):182–222.
  • American College of Obstetricians and Gynecologists Committee on Gynecologic Practice Long-Acting Reversible Contraception Working Group. Committee opinion no. 642: Increasing access to contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol. 2015;126(4):e44–e48.
  • Di Meglio G, Crowther C, Simms J. Contraceptive care for Canadian youth. Paediatr Child Health. 2018;23(4):271–277.
  • Buhling KJ, Hauck B, Dermout S, et al. Understanding the barriers and myths limiting the use of intrauterine contraception in nulliparous women: results of a survey of European/Canadian healthcare providers. Eur J Obstet Gynecol Reprod Biol. 2014;183:146–154.
  • Aoun J, Dines VA, Stovall DW, et al. Effects of age, parity, and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol. 2014;123(3):585–692.
  • Eisenberg DL, Schreiber CA, Turok DK, et al.; ACCESS IUS Investigators. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception. 2015;92(1):10–16.
  • Gemzell-Danielsson K, Apter D, Hauck B, et al. The effect of age, parity and body mass index on the efficacy, safety, placement and user satisfaction associated with two low-dose levonorgestrel intrauterine contraceptive systems: subgroup analyses of data from a phase III trial. PLoS ONE. 2015;10(9):e0135309.
  • Lohr PA, Lyus R, Prager S. Use of intrauterine devices in nulliparous women. Contraception. 2017;95(6):529–537.
  • Merki-Feld GS, Caetano C, Porz TC, et al. Are there unmet needs in contraceptive counselling and choice? Findings of the European TANCO Study. Eur J Contracept Reprod Health Care. 2018;23(3):183–193.
  • Bahamondes L, Mansour D, Fiala C, et al. Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives. J Fam Plann Reprod Health Care. 2014;40(1):54–60.
  • Dina B, Peipert LJ, Zhao Q, et al. Anticipated pain as a predictor of discomfort with intrauterine device placement. Am J Obstet Gynecol. 2018;218(2):236.e1–236.e9.
  • Hladky KJ, Allsworth JE, Madden T, et al. Women’s knowledge about intrauterine contraception. Obstet Gynecol. 2011;117(1):48–54.
  • Brima N, Akintomide H, Iguyovwe V, et al. A comparison of the expected and actual pain experienced by women during insertion of an intrauterine contraceptive device. Open Access J Contracept. 2015;6:21–26.
  • Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012;97(3):616–622.e1–3.
  • Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol. 2013;122(6):1205–1213.
  • Heikinheimo O, Bitzer J, García Rodríguez L. Real-world research and the role of observational data in the field of gynaecology - a practical review. Eur J Contracept Reprod Health Care. 2017;22(4):250–259.
  • Kyleena 19.5 mg intrauterine delivery system – summary of product characteristics. Bayer plc. Last updated 02 May 2019. Available at: https://www.medicines.org.uk/emc/product/769/smpc
  • Kramer RD, Higgins JA, Godecker AL, et al. Racial and ethnic differences in patterns of long-acting reversible contraceptive use in the United States, 2011-2015. Contraception. 2018;97(5):399–404.
  • Ferreira JM, Nunes FR, Modesto W, et al. Reasons for Brazilian women to switch from different contraceptives to long-acting reversible contraceptives. Contraception. 2014;89(1):17–21.
  • Gemzell-Danielsson K, Apter D, Lukkari-Lax E, et al. Overcoming barriers to levonorgestrel-releasing intrauterine system placement: an evaluation of placement of LNG-IUS 8 using the modified EvoInserter® in a majority nulliparous population. Contraception. 2017;96(6):426–431.
  • Kopp Kallner H, Thunell L, Brynhildsen J, et al. Use of contraception and attitudes towards contraceptive use in Swedish women - a nationwide survey. PLoS ONE. 2015;10(5):e0125990.
  • Cook J, Waddington A, Black D, et al. Intrauterine contraception: knowledge and prescribing practices of Canadian health care providers. J Obstet Gynaecol Can. 2019;S1701–2163(18)30992–7.
  • Anthoulakis C, Iordanidou E, Vatopoulou A. Pain perception during levonorgestrel-releasing intrauterine device insertion in nulliparous women: a systematic review. J Pediatr Adolesc Gynecol. 2018;31(6):549–556.e4.
  • Envall N, Lagercrantz HG, Sunesson J, et al. Intrauterine mepivacaine instillation for pain relief during intrauterine device insertion in nulliparous women: a double-blind, randomized, controlled trial. Contraception. 2019;S0010–7824(19)30037–X.
  • Abbas AM, Ragab E, Abd Ellah NH, et al. Effect of topical glyceryl trinitrate cream on pain perception during intrauterine device insertion in multiparous women: A randomized double-blinded placebo-controlled study. J Gynecol Obstet Hum Reprod. 2019;48(9):715–718.
  • Cristobal I, Neyro JL, Lete I. The new LNG-releasing IUS: a new opportunity to reduce the burden of unintended pregnancy. Eur J Obstet Gynecol Reprod Biol. 2015;190:58–64.
  • Gemzell-Danielsson K, Apter D, Dermout S, et al. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. Eur J Obstet Gynecol Reprod Biol. 2017;210:22–28.
  • Nelson AL. LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years. Expert Opin Drug Deliv. 2017;14(9):1131–1140.
  • Mejia M, McNicholas C, Madden T, et al. Association of baseline bleeding pattern on amenorrhea with levonorgestrel intrauterine system use. Contraception. 2016;94(5):556–560.